Company profile
MultiCell Technologies, Inc.
OTC: MCET · Healthcare · Biotechnology
#1082 of 1,418 Healthcare companies by revenue41st-percentile growth
EA Score
——FH —DQ 23GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ listing tenure, growth stability · ↓ Altman-Z, workforce scale
Methodology →Revenue TTM
$805
Rev growth YoY (TTM)
+1532.7%
Net income (FY)
-$380.1k
Employees
2
as of 2026-08-28
Market cap
$50.0k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$49.3k$49.3k2014
Net income-$380.1k-$380.1k2014
Operating income-$722.8k-$722.8k2014
Total assets$126.2k$126.2k2014
Liabilities$1.6M$1.6M2014
Equity-$144.3k-$144.3k2014
Revenue trend
FY2011 – FY2014 · USD
FY11
FY11
FY12
FY13
FY14
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is MultiCell Technologies, Inc.’s revenue?
MultiCell Technologies, Inc. booked $49.3k in FY2014 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -770.7% net margin.
Peers · Healthcare
FutureWorld Corp.——Natural Health Farm Holdings Inc.——INmune Bio, Inc.41DOvation Science Inc.23DDIAGNOS Inc.29DCalidi Biotherapeutics, Inc.19DNeighbors
Providence →Key facts
CEOW. Gerald Newmin
SectorHealthcare
IndustryBiotechnology
HeadquartersWoonsocket, RI
ExchangeOTC: MCET
Employees2
IPO date2000-01-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.